A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab2026-06-100 OA AI NNaga Sumanth Reddy Gopireddy AAbhishek Kumar RRichard J H Smith CCarla M Nester CChristie P Thomas * DOI:10.1093/ckj/sfag198OriginalOriginal request for helpShareSaveAbstract En